D
Blueprint Medicines Corporation BPMC
$88.84 $0.330.37% NASDAQ
Recommendation
Prev Close
$88.51
Volume
121,196
Avg Vol (90D)
987,145
Market Cap
$5.66B
Dividend & Yield
--
52-Week Range
$73.04 - $121.90
P/E (TTM)
--
EPS (TTM)
-$1.07
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Can Amgen Keep the Beat Streak Alive This Earnings Season?
4/29/2025 - Zacks Investment Research
Lord Abbett & CO. LLC Trims Stake in Blueprint Medicines Co. (NASDAQ:BPMC)
4/29/2025 - MarketBeat
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
4/28/2025 - Zacks Investment Research
Needham Adjusts Price Target for Blueprint Medicines (BPMC) Ahead of Q1 Results BPMC Stock News
4/28/2025 - GuruFocus
Blueprint Medicines price target lowered by $3 at Needham, here's why
4/28/2025 - The Fly
Envestnet Asset Management Inc. Buys 3,723 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
4/28/2025 - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Lord Abbett & CO. LLC
4/27/2025 - Ticker Report
Price T Rowe Associates Inc. MD Raises Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)
4/27/2025 - MarketBeat
Canada Pension Plan Investment Board Takes $1.73 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC)
4/26/2025 - MarketBeat
Cerity Partners LLC Purchases New Position in Blueprint Medicines Co. (NASDAQ:BPMC)
4/26/2025 - MarketBeat
Blueprint Medicines (BPMC) to Release Earnings on Thursday
4/26/2025 - MarketBeat
CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards?
4/25/2025 - Zacks Investment Research
Blueprint Medicines Corp (BPMC) Announces Upcoming First Quarter 2025 Financial Results ...
4/25/2025 - GuruFocus
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
4/25/2025 - GuruFocus
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 ...
4/25/2025 - GuruFocus
Price T Rowe Associates Inc. MD Boosts Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
4/25/2025 - Ticker Report
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
4/25/2025 - PR Newswire
Hood River Capital Management LLC Acquires 207,496 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
4/25/2025 - MarketBeat
Guggenheim Capital LLC Sells 3,725 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
4/25/2025 - MarketBeat
Wells Fargo & Company MN Cuts Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
4/25/2025 - MarketBeat
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
4/24/2025 - Zacks Investment Research
Analysts Expect 24% Gains Ahead For The Holdings of FNY
4/24/2025 - ETF Channel
Avoro Capital Advisors LLC Acquires New Shares in Blueprint Medicines Co. (NASDAQ:BPMC)
4/23/2025 - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) is Rock Springs Capital Management LP's 5th Largest Position
4/23/2025 - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Marshall Wace LLP
4/23/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$508.82M
EBITDA (TTM)
-$195.75M
EBIT (TTM)
-$212.05M
Net Income (TTM)
-$67.09M
Balance Sheet
Total Assets (Q)
$1.18B
Total Debt (Q)
$724.28M
Total Liabilities (Q)
$881.15M
Book Value Per Share (Q)
$4.69
Cash Flow
Cash from Operations (TTM)
-$192.59M
Cash from Investing (TTM)
-$47.50M
Cash from Financing (TTM)
$273.11M
Net Change in Cash (TTM)
$32.12M
Filings
Filing Date
Thursday, February 13, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Beginning of May (est)
Price History
Loading...
Beta
0.96
7-Day Total Return
4.90%
30-Day Total Return
-3.58%
60-Day Total Return
-21.05%
90-Day Total Return
-6.87%
Year to Date Total Return
1.88%
1-Year Total Return
-4.58%
2-Year Total Return
72.50%
3-Year Total Return
52.25%
5-Year Total Return
47.75%
52-week Low
Apr 09, 2025 - $73.04
52-week High
Jul 16, 2024 - $121.90
Valuation
Market Cap
$5.66B - Mid Cap
Enterprise Value
$5.52B
Price/Sales (TTM)
11.06
Price/Book (Q)
18.88
Dividends and Shares
Shares Outstanding
63.60M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.blueprintmedicines.com
Phone Number
(617) 374-7580
Address
45 Sidney Street
Cambridge, MA 02139
Country
United States
Year Founded
2008
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is... more
NASDAQ 04/29/2025 11:41AM Eastern Quotes delayed